





# Madagascar

African Region



## I. Epidemiological profile


Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	21,300,000	88	Plasmodium species: <i>P. falciparum</i> (96%), <i>P. vivax</i> (4%)
Low transmission (0-1 cases per 1000 population)	2,960,000	12	Major anopheles species: <i>An. funestus</i> , <i>An. gambiae</i> , <i>An. arabiensis</i>
Malaria-free (0 cases)	0	-	Reported confirmed cases (health facility): 744,103    Estimated cases: 2,400,000 [1,500,000 ; 4,000,000]
Total	24,240,000	-	Confirmed cases at community level: 193,138    Reported deaths: 841    Estimated deaths: 6,000 [180 ; 13,000]

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2004	First-line treatment of unconfirmed malaria	AS+AQ	2006					
	ITNs/ LLINs distributed to all age groups	Yes	2009	First-line treatment of <i>P. falciparum</i>	AS+AQ	2006					
IRS	IRS is recommended	Yes	1993	Treatment failure of <i>P. falciparum</i>	QN	2006					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN	2006					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	2006	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2006	Type pf RDT used		P.f + all species (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	2006								
Treatment	ACT is free of charge for all ages in public sector	Yes	2006	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	2006	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2015	AL	2006-2006	1.7	1.7	1.7	28 days	1	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	AS+AQ	2006-2013	0	0	8.7	28 days	18	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-	<b>Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)</b>							
	Directly observed treatment with primaquine is undertaken	Yes	2015	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
System for monitoring adverse reactions to antimalarials exists	Yes	2008	2010-2015	Yes	Yes	Yes	No	<i>An. funestus</i> s.l., <i>An. gambiae</i> s.l., <i>An. mascarensis</i>			
Surveillance	ACD for case investigation (reactive)	Yes	2003								
	ACD of febrile cases at community level (pro-active)	Yes	1993								
	Mass screening is undertaken	Yes	2003								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	2006								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	Yes	2008									

## III. Financing

Sources of financing




Government expenditure by intervention in 2015




## IV. Coverage

Coverage of ITN and IRS




Cases tested and treated in public sector




## V. Impact


Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths (per 100 000)

